Originator Company: National Institute of Dental and Craniofacial Research Active Companies: National Institute of Dental and Craniofacial Research; National Institutes of Health
inhibitors, for the potential prevention and treatment of head and neck squamous cell carcinoma (HNSCC), and also investigating other mTOR inhibitors, for the potential prevention of mucositis and hair loss in patients undergoing chemotherapy and stem cell transplantation [ 1395222 ], [ 1424377 ]. In August 2010, a phase I/II trial was initiated in HNSCC; in January 2013, enrollment was ongoing [ 1424377 ]; in May 2015, data from the trial were presented [ 1664652 ]. By September 2012, in vivo and
Dermatologic; Gastrointestinal; Cancer
Phase 2 Clinical
mTOR inhibitor
Anticancer
Alopecia; Head and neck tumor; Mucositis